ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1576

Clinicopathological Characteristics of Adult IgA Nephropathy: A Retrospective Cohort Study

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Caster, Dawn J., University of Louisville, Louisville, Kentucky, United States
  • Abner, Clint, Arkana Laboratories, Little Rock, Arkansas, United States
  • Ararat, Kerime, Arkana Laboratories, Little Rock, Arkansas, United States
  • Walker, Patrick D., Arkana Laboratories, Little Rock, Arkansas, United States
  • Yakubu, Amin, Genesis Research, LLC, Hoboken, New Jersey, United States
  • Bunke, Martin C., Travere Therapeutics Inc, San Diego, California, United States

IgA nephropathy (IgAN) is the most common form of primary glomerular nephropathy and a leading cause of chronic kidney disease (CKD). These analyses characterize clinical and histological features of IgAN in adults at time of kidney biopsy.


A retrospective study of clinical and histologic characteristics was performed in patients (pts) ≥18 yrs of age with ≥1 IgAN positive kidney biopsy without prior kidney transplant reported from Arkana Laboratories (Jan 1, 2016-May 30, 2020). Estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi equation without race modifier. All results are at the time of biopsy.


Of 67,262 kidney biopsies performed during the study period, 4,384 (6.5%) IgAN positive cases met the study criteria and were included, of which, 62.7% were male, 49.6% White, 5.1% African American, 5.3% Hispanic, 5.6% Asian and 34.4% Unknown/Other race/ethnicity. Mean (SD) age at biopsy was 47.7 (16.6) yrs. Urine protein to creatinine ratio/ 24-hour urine protein data were available for 52.4% of pts and the median (Q1-Q3) was 3.0 (1.0 – 5.0) g/g. Additionally, 65.2% of pts had hypertension, 63.1% had known hematuria, 25.7% had severe arteriosclerosis, 15.8% had severe arteriolosclerosis, and 27.2% and 20.9% of patients had CKD stage 3 and 4, respectively. The mean (SD) eGFR was 42.4 (32.1) mL/min/1.73m2. Immunofluorescence, sclerosis, and fibrosis characteristics are presented in Table 1.


The large proportion of pts diagnosed at CKD stage ≥3 and high MEST-C scores for S and T suggest significant disease duration at the time of biopsy. Earlier intervention may be of value to prevent ESKD.


  • Commercial Support